Koyuan Pharmaceutical: Subsidiary's drug has been approved and is expected to be selected for centralized procurement.

Keyuan Pharmaceutical announced that its wholly-owned subsidiary, Linuo Pharmaceutical, has recently received the approval notification for a drug supplement application, and the holder of the marketing authorization for Betamethasone Hydrochloride Tablets has been changed to Linuo Pharmaceutical. Meanwhile, Linuo Pharmaceutical participated in the 12th batch of the national centralized procurement of drugs and is expected to be selected for products such as Injectable Isavuconazole, and the enterprise for Betamethasone Hydrochloride Tablets is also expected to be changed to Linuo Pharmaceutical. The procurement period will run from the date of the selection results until December 31, 2029. This approval and expected selections may enhance performance, but uncertainties remain in the future.